8-K: Monogram Orthopaedics Provides FY 2023 Update and Regulatory Strategy

Monogram Orthopaedics released an investor presentation detailing their financial results for 2023 and provided an update on their regulatory strategy for their mBs robotic system.

Summary

• Monogram Orthopaedics provided a financial and operational update for the year ended December 31, 2023.
• The company reported a cash balance of $13,589,028 and accounts receivable of $364,999 as of December 31, 2023.
• Operating cash flow for the year was $13,542,509, with a monthly burn rate of approximately $1.1 million.
• Monogram is developing the mBs robotic system, a Class II risk device, and is pursuing 510(k) clearance.
• The company has had three formal FDA pre-submission communications and plans a fourth in April.
• Management believes the semi-active version of mBs has a lower risk of requiring clinical data for FDA clearance compared to the active version.
• Monogram is also planning an overseas clinical trial with 88 total knee arthroplasty (TKA) surgeries across three sites.
• The company is targeting a 510(k) submission in the second half of 2024.
• Monogram has identified risks including hardware and software testing, ISO 60601 compliance, resource constraints, and human factors testing.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress on regulatory strategy and product development, but also acknowledges risks and challenges. The company has a strong cash position but is also burning cash at a significant rate.

Positives

• Monogram has a strong cash position of $13.6 million.
• The company has no traditional debt or warrant obligations.
• A strategic investor converted a warrant for $1.25 million in cash.
• Management believes the semi-active version of mBs reduces the risk of an FDA clinical data request.
• The company has made progress on regulatory submissions with three formal FDA pre-submission communications.
• Monogram has identified sites, a CRO, PIs, and a distributor for its overseas clinical trial.
• The company has completed radiated and conducted emissions testing.
• Monogram has a highly variable cost structure.

Negatives

• The company has a monthly burn rate of approximately $1.1 million.
• There is still a risk of an FDA clinical data request for the mBs system.
• The regulatory timeline is subject to risks including hardware and software testing, ISO 60601 compliance, resource constraints, and human factors testing.
• Human factors testing is reliant on a significant number of surgeons, which can be difficult to schedule.
• The company's timeline targets are not guarantees and are subject to risk.

Risks

• There is a risk of an FDA clinical data request for the mBs system.
• The regulatory timeline is subject to risks including hardware and software testing, ISO 60601 compliance, resource constraints, and human factors testing.
• Human factors testing is reliant on a significant number of surgeons, which can be difficult to schedule.
• The company's timeline targets are not guarantees and are subject to risk.
• There are approximately 60 hardware and system test protocols and approximately 101 software test protocols that need to be completed.
• ISO 60601 3rd party risk remains a concern.
• Resource constraints may impact the timeline.

Future Outlook

Monogram is targeting a 510(k) submission in the second half of 2024 and plans to initiate an overseas clinical trial. The company expects sufficient access to cash through 510k approval.

Management Comments

• Management believes the risk of an FDA clinical data request for mBs active version is too high.
• Management believes the technical differences of concern relating to active vs. semi active control could be mitigated.
• Management believes mBs semi active version has closer equivalence to Mako and Velys and lessens the risk of a clinical trial request.
• Management sees reduced risk with remaining tests (which have been largely simulated in house).

Industry Context

The presentation highlights the competitive landscape in robotic-assisted orthopedic surgery, noting Stryker's dominance with its Mako system. Monogram aims to differentiate itself by offering a more cost-effective and versatile solution with its mBs system.

Comparison to Industry Standards

• Monogram is comparing its mBs system to established robotic surgery systems like Stryker's Mako, Zimmer Biomet's ROSA, and DePuy Synthes' Velys.
• The company notes that Mako had a 75% market share in robotic knees, while ROSA had 8% and Velys had 2% in 2022.
• Monogram is aiming to achieve similar or better outcomes with its semi-active mBs system, while reducing costs and improving efficiency.
• The company is also highlighting the fact that Mako's stock was down 75% six months before its acquisition by Stryker, suggesting that the market for robotic surgery is volatile.

Stakeholder Impact

• Shareholders are provided with an update on the company's financial status and progress on product development.
• Employees are working on the development and regulatory approval of the mBs system.
• Surgeons are involved in human factors testing and will be the end-users of the mBs system.
• Customers (hospitals and patients) will benefit from the potential advantages of the mBs system, such as reduced costs and improved outcomes.
• Suppliers are involved in the manufacturing and supply chain of the mBs system.

Next Steps

• Monogram plans to have a fourth formal FDA pre-submission communication in April.
• The company aims to complete V&V largely in the first half of 2024.
• Monogram is targeting a 510(k) submission in the second half of 2024.
• The company will initiate an overseas clinical trial with 88 TKA surgeries.
• Monogram plans to scale to other applications and patient-optimized 3D printed implants.

Key Dates

Keywords

Orthopaedics, Robotics, mBs, 510(k), FDA, Regulatory, Clinical Trial, TKA, Implants, Surgery